Physician profile
Michael Mihalick
NPI 1477557213
$2,572.76
in general payments reported to CMS, 2019-2025
23 companies · $214 in 2025
The $214 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.43 · 2020: $126 · 2021: $233 · 2022: $944 · 2023: $506 · 2024: $487 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,207.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $385.29 | 2020-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $375.35 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $279.73 | 2021-2023 | Xarelto |
| Impulse Dynamics (USA) INC. | $255.24 | 2022-2024 | Optimizer, Optimizer |
| Boston Scientific Corporation | $187.00 | 2020-2024 | Watchman Access System, Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.65 | 2022-2025 | Jardiance |
| Pfizer INC. | $113.34 | 2020-2022 | |
| Abbott Laboratories | $97.22 | 2022-2025 | Ensite Precision, Cardiomems |
| Edwards Lifesciences Corporation | $87.18 | 2019-2022 | |
| Novo Nordisk INC | $82.56 | 2022-2025 | |
| Irhythm Technologies, INC. | $72.23 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Biosense Webster, INC. | $68.63 | 2023-2024 | Carto 3 |
| Amgen INC. | $65.10 | 2022-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $64.10 | 2022-2023 | |
| Preventice Services, LLC | $62.88 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $52.27 | 2020-2021 | |
| Itamar Medical INC | $29.38 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $27.92 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $26.30 | 2024 | |
| Amarin Pharma, INC. | $23.07 | 2022 | |
| Cvrx, INC. | $19.27 | 2022 | |
| Esperion Therapeutics, INC. | $16.44 | 2023 | Nexletol |
| Elutia, INC. | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mihalick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.